News

For Immediate Release: June 2, 2015

Contact
Mary Kuramoto
513-579-9911 x2523
m.kuramoto@medpace.com

Medpace Experts Presenting at DIA on Rare Disease Clinical Development and Pharmacovigilance “Power of Giving” Campaign Continues on Exhibit Floor

CINCINNATI, OH — (June 2, 2015) – Medpace speakers will be participating in two sessions at DIA 2015 51st Annual Meeting gathering in Washington, DC, June 14-18. As a global full-service CRO with over 20 years of experience working with drug, biologic and medical device sponsors, Medpace has earned a reputation for adeptly managing complex and challenging clinical studies. Two of the company’s experts—Michelle Petersen and Michael Baptist—will share their insights and experience in the following sessions.

Orphan Drug Development Challenges: Case Studies

Wednesday, June 17th, 10:30-12:00 pm, Room 145B

Michelle Petersen, MS, Clinical Trial Manager at Medpace, will share lessons learned and best practices for managing rare disease/orphan drug trials. As part of a 3-person symposium, Michelle will showcase how strategic planning and operational efficiency is critical for efficient and successful development of an orphan drug program in her presentation titled: Connecting the Dots for Fast-Track Approval for Rare Disease and Orphan Drugs.

Pharmacovigilance Inspections: Achieving Compliance in a Global Environment

Wednesday, June 17, 10:30am – 12:00pm, Room 207A: Level Two South

Michael Baptist, Quality Assurance Manager at Medpace, will participate in a 3-person session that will provide an overview on the coordination of pharmacovigilance inspections in the EU and the US (including pharmacovigilance inspection metrics). Specifically, Mr. Baptist will present the topic: Pharmacovigilance Audits: Is the US Behind the Curve?

The Power of Giving – DIA attendees Invited to Choose a Charity

In addition, the company announced it will be continuing its “The Power of Giving” campaign at booth 1801 on the DIA exhibit floor. The campaign was introduced earlier this year and aligns with the company’s key therapeutic and specialty areas in which it designs and executes clinical trials for drug, biologic and medical device sponsors. Medpace is inviting DIA attendees stop by booth 1801 to “choose a charity” to which a $5 contribution will be made. A maximum of $5000 will be donated to each charity at the end of the year.

The six charities include:

  • American Heart Association (cardiovascular and stroke research)
  • American Diabetes Association (metabolic and endocrine research)
  • American Cancer Society (oncology and hematology research)
  • amFAR – Foundation for AIDS research (infectious disease research)
  • Rare Disease Foundation (rare disease and orphan indication research)
  • Children’s Miracle Network (pediatric research).

ABOUT MEDPACE

Medpace is a scientifically-driven, global full-service clinical contract research organization (CRO) providing Phase I-IV clinical development services for drug, biologic, and device programs. Medpace’s physician-led, high-science, and disciplined operating approach leverages regulatory and therapeutic expertise to accelerate the global development of safe and effective medical therapeutics across all major areas including oncology, cardiovascular, metabolic/diabetes, infectious disease, and neuroscience. Headquartered in Cincinnati, Ohio, Medpace employs approximately 2,500 people worldwide with operations in 35 countries.

For more information, please visit www.medpace.com